2025Year8Month19Day (Yesterday), the globally renowned medical technology giant Medtronic (Medtronic) Announces Major Personnel and Strategic Initiatives:Appointment of Two New Board Members and Engagement with Activist Investor Elliott Investment Management (Elliott Investment ManagementAfter conducting "constructive engagement" with Medtronic (one of the largest shareholders of Medtronic), two special committees were established.

During the earnings call, Medtronic CEO Jeff·Martha (Geoff Martha") disclosed to investors that the addition of two board seats and the formation of a special committee are the results of 'collaboration' with Elliott, aiming to help the company seize the 'tremendous opportunities ahead and fully unlock Medtronic's potential.'"

Medtronic Board's Appointment Decision Effective Immediately,Introducing John, former CEO of Medtronic·Grotolars (John Groetelaars) and previousStrykerCFO Bill·Jerison (Bill Jellison) Serve as an independent director.Martha said that the two new members"Profound experience in medical technology will bring a strong voice to the board." He admitted that although Medtronic has accumulated experience in the medical technology field, it has recently lacked such experience. "Therefore, the joining of Grootlaars and Jerrison will play an important role."

As part of the strategic adjustment, Medtronic has simultaneously established two special committees.One is the Growth Committee, which will focus on mergers and acquisitions, R&D, and potential asset divestitures; the other is the Operations Committee, primarily concentrating on improving operational performance, expanding profit margins, and accelerating sustainable profitability.

According to a statement by Medtronic, Grootelaars and Jelison will serve on one or both of these committees, while Martha will personally chair the committee.

Mark, Partner at Elliot Law Firm·Steinberg (Marc Steinberg")" In the statement, it was pointed out that Elliott's decision to become a significant investor in Medtronic is based on the belief that Medtronic is "entering a new chapter," characterized by accelerated growth, improved operations, and a clearer strategic focus.

Steinberg said:"We firmly believe that Medtronic's recent innovative initiatives in some of the most attractive markets in the medical technology field have driven a turning point in the company’s organic growth. Coupled with a renewed focus on simplifying the product portfolio and improving operational execution, Medtronic's profit growth will continue to accelerate."

Martha also emphasized in the statement that the establishment of new board members and committees is an important example of Medtronic moving towards a more streamlined and profitable direction, and mentioned the company's plan to spin off its diabetes division.

JPMorgan Chase (J.P. Morgan) Analysts noted in investor reports released ahead of Medtronic's earnings call that the appointment of new board members sends a positive signal, "demonstrating management's increased commitment and showing they deeply understand the need for change to enhance shareholder value."

According to the announcement, Grotolars and Jelison will be nominated to participate in Medtronic.2025Annual General Meeting of Shareholders for the election of the board of directors. In addition, Medtronic plans to2026Held in the middle of each year, the Investor Day event will provide a detailed introduction to the progress of the new committee's work.

As of2025Year7Month25In the latest financial quarter of the day,MedtronicSubmitted a solid performance report. The financial report shows that the company achieved sales in the quarter.85.78Billion USD, net profit reached10.47USD billion, equivalent to earnings per share81U.S. cents. Although the net profit slightly declined year-over-year, the top-line sales growth was significant, with a year-over-year increase of over8%(Organic growth rate excluding the impact of exchange rates, etc.)4.8%）。

Under non-GAAP (Non-GAAP), excluding the impact of one-time items, Medtronic's earnings per share were1.26Dollars, exceeding the previous expectations of Wall Street analysts1.23The consensus expectation for the US dollar, and the revenue side also exceeds analysts' forecasts.83.7Billion-dollar forecast.

Medtronic Adjusts Tariff Impact Expectations in Earnings ReportThe company now expects that tariff factors will impact its profitability for the current fiscal year by approximately1.85Negative impact of hundreds of millions of dollars, compared to previous2Up to3.5The estimated range in billions of dollars has narrowed significantly.Thanks to the easing of import tax pressures, Medtronic will adjust its guidance range for earnings per share.5.50-5.60Medtronic revised upwards to5.60-5.66USD.

In terms of revenue growth guidance, the company maintains organic revenue growth of approximately5%The expectation, while raising the forecast for reported revenue growth to6.5%-6.8%。This adjustment reflects the company's confidence in business resilience.

Medtronic CEO Jeff·Martha (Geoff Martha") We achieved solid mid-single-digit organic revenue growth this quarter, primarily driven by contributions from multiple innovative product categories such as pulsed field ablation, transcatheter valves, neuromodulation, diabetes, and leadless pacemakers. As we make substantial progress in our core growth areas, we are confident in accelerating revenue growth in the second half of the year."

Despite beating expectations, Medtronic's stock still fell over in early trading today.3%, Report89.14Dollar/Stock.TruistSecurities analysts said that the stock price adjustment was within the market's expected range. The institution maintained its "Hold" rating on Medtronic shares and noted: "Institutional investors previously expected Medtronic's organic revenue growth in the first quarter to be5.5%, actual4.8%"Although the growth rate is slightly lower than this expectation, considering the overall market environment, this performance is still considered stable."

Market analysis suggests that the short-term fluctuations in Medtronic's stock price may be related to investors' concerns about the revaluation of the medical technology sector. In the long term, the company’s strategic focus on core businesses, optimization of product portfolios, and improvement of operational efficiency are expected to continue unlocking value.。Medical Device News will continue to follow up on further actions after the establishment of Medtronic's two major committees.